Docusign Envelope ID: 305A85A8-8AD4-8AE4-8122-F6BDC1A8E87A

Registered number: 11943477
Charity number: 1185091

FOLLICULAR LYMPHOMA FOUNDATION

(A company limited by guarantee)

AUDITED TRUSTEES' REPORT AND FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2025



signature:2c9944044a7bf5cc9d6f47e5b64eda16c36386dbf7ba586cd2a72f7cff17934

Docusign Envelope ID: 305A85A8-8AD4-8AE4-8122-F6BDC1A8E87A

FOLLICULAR LYMPHOMA FOUNDATION
(A company limited by guarantee)

CONTENTS

	Page
Reference and administrative details of the Company, its Trustees and advisers	1
Trustees' report	2 - 13
Independent auditor's report on the financial statements	14 - 17
Statement of financial activities	18
Balance sheet	19
Statement of cash flows	20
Notes to the financial statements	21 - 36

signature:2c9944044a71f5cc6d6f47c3b84e1da16c36398dbf7ba586cd2070f7cff17034

Docusign Envelope ID: 305A85A8-8AD4-8AE4-8122-F6BDC1A8E87A

FOLLICULAR LYMPHOMA FOUNDATION

(A company limited by guarantee)

REFERENCE AND ADMINISTRATIVE DETAILS OF THE COMPANY, ITS TRUSTEES AND ADVISERS FOR THE YEAR ENDED 31 DECEMBER 2025

Trustees	Lady N S Mendelsohn, Chair Lord J N Mendelsohn Lord R I Harrington P M V Thompson A Wong J J Burley Dr J W Simons
Company registered number	11943477
Charity registered number	1185091
Registered office	417 Finchley Road London NW3 6HJ
Chief executive officer	E France (appointed 1st February 2025)
Independent auditor	Cooper Parry Group Limited Cubo Birmingham 4th Floor Two Chamberlain Square Birmingham B3 3AX

signature:2c9944044a71f5cc6d6f47c5b64e1da1[illegible]

FOLLICULAR LYMPHOMA FOUNDATION

TRUSTEES' REPORT
FOR THE YEAR ENDED 31 DECEMBER 2025

The Trustees, who are also the directors of the charity for the purposes of the Companies Act 2006, present their report together with the financial statements for the year ended 31 December 2025. The financial statements have been prepared in accordance with the Charities SORP (Statement of Recommended Practice), applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102), effective 01 January 2019.

1. Objectives and Activities

Our mission is to help those with follicular lymphoma, a currently incurable blood cancer, to live well and get well by finding and funding the best research to identify breakthroughs that will change how we understand and treat the condition. We provide follicular lymphoma-focused information resources for patients and work to ensure patients' voices are at the heart of the search for better treatments and a cure.

More specifically, the Charity's objectives are the following:

A. To sponsor basic and translational research to assist in the development of better treatments and a cure for follicular lymphoma including sponsoring the establishment of an international challenge to scientific and clinical researchers to focus on prospective cures.

B. To support the promotion of the "patient voice", by supporting patient advocacy and education, the development of patient communities and evaluating the efficacy of patient-reported outcomes on current treatments and side effects to assist clinicians and patients.

C. To improve health outcomes by way of stimulating research and evaluation of complementary conditions to supplement medical treatment.

Public Benefit - The Trustees confirm that they have complied with their duty to have due regard to the Charity Commission's public benefit guidance when reviewing the charity's objectives, activities and future plans. The Trustees consider that the charity's activities provide public benefit by funding research into follicular lymphoma, supporting the development of better treatments and approaches to care, providing trusted information and support for people affected by follicular lymphoma, and ensuring patient experience helps shape research, education and engagement priorities.

2. Achievements and performance

2025 was a year of focused progress for the Follicular Lymphoma Foundation (FLF). Scientific understanding advanced, new treatment approaches moved closer to patients, and expectations of what is possible continued to shift. FLF turned urgency into practical momentum by funding research that targets the biggest barriers to cure, engaging patients at scale and building the partnerships needed to move promising science further and faster.

In 2025, FLF invested in cure-focused research and patient programmes, supported active translational research programmes addressing relapse, treatment resistance and treatment durability, captured patient experience through global survey responses and wider community engagement, and directed the majority of expenditure toward research and patient programmes.

Together, this shows a clear model in which donor support enables research, research creates pathways to patient benefit, and patient insight ensures progress is anchored in what matters most in real life.

"When I look at what has been achieved in 2025, I feel a powerful mix of pride and determination. Pride, because the progress is real. Determination, because it is not yet enough. Every study, every data point and every collaboration is a step toward the future patients deserve: one where follicular lymphoma is no longer a life-defining diagnosis. Cure cannot wait. Neither can we." - Nicola Mendelsohn CBE, Founder and Chair, Follicular Lymphoma Foundation

2.1. Research programmes

The FLF's research programmes are designed to turn promising science into better patient outcomes for people affected by follicular lymphoma. Each programme addresses an important unmet need, with the potential to improve treatment and move closer to cure. At the heart of every programme is a clear "so what?": what this could change for patients, what new evidence it could generate for the field, and how FLF's support helps improve patient outcomes sooner.

2.1.1. The CURE FL Awards

The CURE FL (Curative Research to Eliminate Follicular Lymphoma) Awards were the first round of FLF's CURE FL Programme, designed to answer one of the biggest questions in follicular lymphoma: why does the disease return after powerful immune-based treatments, and how can we stop it? This programme ran from December 2022 to July 2025 in collaboration with the Milken Institute, deploying approximately $2 million across four translational research projects. Each project received $500,000 over two years. The focus was on transformative projects addressing relapse and treatment resistance after immunotherapy, areas FLF identified as having the greatest potential to generate evidence that could lead to better therapies reaching patients sooner.

What it made possible
The CURE FL Awards helped move promising scientific discoveries closer to the people who need them most. Across four translational research projects, the programme generated new insights into treatment resistance and relapse after immunotherapy, strengthened understanding of the biological mechanisms that drive relapse, and helped advance promising discoveries from the laboratory towards patient studies. The programme also generated evidence, collaborations and new scientific insights that extend beyond follicular lymphoma, helping inform research across the wider lymphoma field.

What we learned
The CURE FL Awards showed that relapse after immunotherapy is not an immovable barrier. The funded projects generated new insights into immune escape, treatment resistance and how treatment responses could become deeper and more durable. Two projects progressed to the final preclinical stages required before potential testing in patients, with one of these going on to inform two clinical studies. A third project met its objectives by validating a potential new strategy to prevent relapse and generating the evidence needed to move that approach closer to patients. The fourth generated useful insights that continue to inform the field, and FLF will continue to monitor future developments arising from this work.

Why it matters
Collectively, these outcomes demonstrate how translational research can advance understanding, inform future studies and help bring cure closer for people living with follicular lymphoma. By answering critical questions about why treatment stops working and what drives relapse, the programme is helping identify new approaches that could lead to more durable responses and improved outcomes for people living with FL. The knowledge generated may also help inform research into related blood cancers that share similar biological pathways.

Read more

2.1.2. Research United to CURE FL Awards

Building on the first CURE FL Awards, Research United to CURE FL is the second round of FLF's CURE FL Programme. Launched in 2024 in partnership with Blood Cancer United, formerly the Leukaemia & Lymphoma Society, and the Institute for Follicular Lymphoma Innovation, the partners awarded $2.25 million to three promising follicular lymphoma research projects.

What it focuses on
Research United to CURE FL supports translational research designed to move scientific ideas closer to clinical trials and patient benefit. The funded projects focus on three areas with clear relevance to patients: understanding resistance to immune-based treatments, developing more precise targeted therapies, and testing a chemotherapy-free first-line treatment approach.

Why it matters
As treatment options grow, the challenge is not only finding new therapies but knowing how to use them better. Patients need treatment approaches that are more precise, less toxic, and more likely to deliver deep, lasting responses. The biological questions these projects address are also relevant beyond follicular lymphoma, with the potential to inform research into related blood cancers.

2025 progress
In 2025, the Research United to CURE FL projects advanced novel targeted therapies, completed enrolment to a 35-patient chemotherapy-free clinical trial with encouraging early results, and generated new biological samples, data and research models to better understand why follicular lymphoma can persist or return after treatment. Together, the projects delivered their first planned outputs and generated findings that will inform the next phase of research.

Read more

2.1.3. The FL Biomarker Discovery Programme

Launched in 2024 with projects activated in March 2025, FLF partnered with The Mark Foundation for Cancer Research on the FL Biomarker Discovery Programme. This partnership supports research to identify biological markers that could help predict how follicular lymphoma behaves and how patients may respond to treatment. Over time, biomarkers could help support new treatment approaches and potentially preventative strategies. The programme was developed with scientific, clinical and patient input. It focuses on key moments in higher-risk disease, including transformation, early relapse and the early biological changes that can lead to follicular lymphoma.

What it focuses on
A biomarker is a biological signal, such as a molecule, protein, or gene, that can help predict what is happening in the body and what may happen next. Reliable biomarkers for follicular lymphoma do not currently exist. This programme supports research using advanced technologies to better understand follicular lymphoma tumours, the immune cells around them, and the patterns that may be linked to relapse, transformation, or treatment response.

Why it matters
Biomarkers could mean clearer answers at moments of uncertainty: who may need treatment straight away, who may be at higher risk of relapse or transformation, and which treatment approach may be most appropriate. For patients and clinicians, this could support more personalised decisions, reduce unnecessary treatment and
enable earlier action when needed.

2025 progress
In 2025, the two selected projects were awarded, supporting research at The University of Texas MD Anderson Cancer Center and Yale School of Medicine. The two-year funded projects use advanced spatial technologies to study follicular lymphoma tumours and their surrounding immune environment. Together, they aim to identify patterns that could predict prognosis, progression, transformation, and response to treatment.

Read more

2.1.4. PETReA Plus Programme

PETReA Plus is a UK-based observational study generating critical data from people newly diagnosed with follicular lymphoma. Led by Professor Kim Linton at The University of Manchester, the programme runs from September 2024 to September 2029 and is funded in partnership with Blood Cancer UK and The Joyce and Norman Freed Charitable Trust. The study is designed to help clinicians and patients make more informed, personalised decisions about treatment in the future. It is contributing to what is expected to become one of the largest global resources of follicular lymphoma data and patient samples, creating a resource that could support future research well beyond this individual study.

What it focuses on
PETReA Plus is collecting outcomes from the initial management of people newly diagnosed with follicular lymphoma. It sits alongside PETReA, an international trial focused on understanding the best use of rituximab according to different risk groups.

Why it matters
As treatment options grow, one of the most important questions is how to use them well. PETReA Plus will help address knowledge gaps that cannot be answered through current clinical trials alone. By capturing evidence from routine care, the study could help link different diagnoses and treatment approaches with different outcomes, supporting more personalised care, better-informed decisions and fewer unnecessary toxic treatments.

2025 progress
With a target of recruiting 500 patients from 65 sites in the UK, the PETReA Plus study team made consistent progress in 2025 towards preparing for recruitment. By December 2025, the first patient had been recruited to the study.

"The real determinant of whether a study sinks or swims is how popular it is with local sites – how many sites want to run the study and how enthusiastic they are about recruiting patients. I see the whole spectrum across my area of clinical research, and I have to say this one is flying, now the sites are starting to open." - Dr Andy Pettitt, co-investigator on the PETReA Plus study

Read more

2.2. People affected by follicular lymphoma at the heart of our work

The FLF supports people today while learning from lived experience to shape tomorrow. People affected by follicular lymphoma help inform the charity's research, patient information and future programmes through surveys, discussion sessions and patient representatives, ensuring the work remains grounded in the outcomes that matter most in real life.

2.2.1. Patient support and education
Living with follicular lymphoma raises questions about diagnosis, treatment, uncertainty and where to find reliable support. FLF provides accessible, expert-informed information based on up-to-date evidence, along with opportunities to hear from experts and others affected by the disease.

In 2025, 14,438 people used Your Support Hub on the FLF website for trusted information and support, 22,765 webinar views connected patients and caregivers with expert insight and lived experience, and 123,000 views of patient stories helped people feel less alone and more informed.

This support has immediate practical value: people are better equipped to understand follicular lymphoma, prepare for conversations with their healthcare teams and make informed decisions about their care. It also helps people feel less alone and more connected to a community that understands what they are facing. Over time, better information also supports the FLF's wider mission. When people understand research, clinical studies and the role of patient participation, they are better placed to engage with opportunities that can help develop new treatments and move the field closer to cure.

"I very much appreciate everything that this team puts together to keep your global audience and patients 'in the know' and well informed. I think you do an absolutely amazing job on such a large scale." Anonymous response to the FLF patient survey

2.2.2. The patient voice

People affected by follicular lymphoma help shape FLF's research, patient information and future programmes through surveys, discussion sessions and patient representatives. Patient insight ensures FLF focuses not only on what is scientifically possible, but also on the outcomes that matter most to people living with follicular lymphoma, from reducing uncertainty and improving communication to supporting informed treatment decisions.

In 2025, patient insight helped inform research strategy, global patient survey content and interpretation, scientific education for healthcare professionals, and events and partnerships focused on improving patient outcomes. This brings FLF closer to cure by grounding scientific priorities in real patient experience, so research focuses on what could make the greatest difference in people's lives.

35 highly engaged patient contributors helped shape FLF's research and patient information, 1,042 responses were received through FLF's global patient survey, and more than 100 countries were represented through community engagement and wider networks.

An example of patient insight in action

Through the Global Patient Survey and focus groups in 2025, people affected by follicular lymphoma helped shape FLF's global patient survey through a face-to-face workshop. Through further online discussions, they also played a key role in interpreting the findings. Their insight highlighted the real-life importance of treatment preferences, uncertainty, communication and decision-making about clinical trials.

The difference it made: these insights were shared directly with researchers and healthcare professionals at forums such as the American Society of Haematology symposium and FLF investigator workshops, helping ensure research and care are shaped by patient priorities.

By bringing the patient voice into global decision-making, this work supports more meaningful shared decision-making and helps patients access the treatments that are right for them.

"I was actually quite anxious prior to the meeting but quickly felt it so worthwhile. Hearing the views of others living with FL and being heard was important. The opportunity to help is huge." Lived Experience Discussion Attendee

2.3. Mobilising funding and partnerships

Cure for follicular lymphoma will not come from one individual, one organisation, one discipline or one type of expertise acting alone.

FLF brings together researchers, clinicians, data specialists, industry partners, philanthropic funders and people living with follicular lymphoma around shared priorities, so that funding, expertise and patient insight can work harder together. This helps ensure the most promising science reaches people faster and moves follicular lymphoma closer to cure.

"Progress depends on collaboration. No single organisation can move the field alone, but together we can protect momentum, align effort and keep patients at the centre." Emma France, Global CEO, The FLF

2.3.1. What partnership made possible in 2025

Larger, more ambitious research programmes
Strategic partnerships enabled FLF to pool expertise and funding around larger, more ambitious research programmes, including Research United to CURE FL, the FL Biomarker Discovery Programme and PETReA Plus.

A stronger bridge across fields
FLF connected expertise from lymphoma research, immunology, clinical care, drug development, philanthropy and patient experience, so promising work was shaped by more than one field from the start.

Trusted patient education and insight
FLF delivered patient education, preference research, webinars and healthcare professional engagement, keeping patient need at the centre.

A shared case for collaboration

FLF co-authored an article with the Institute for Follicular Lymphoma Innovation and Blood Cancer United on the importance of collaboration in accelerating progress for people living with follicular lymphoma.

2.3.2. Key global partners in 2025 included:

The Mark Foundation for Cancer Research - Supporting high-impact cancer research that accelerates breakthroughs in how cancer is understood and treated. Co-funded the FL Biomarker Discovery Programme.

Milken Institute Center for Strategic Philanthropy - Collaborating with the FLF to strengthen strategic philanthropy, accelerate research and advance patient-focused innovation.

The Institute for Follicular Lymphoma Innovation - Advancing research and innovation to support the development of more targeted therapies for follicular lymphoma.

Blood Cancer United - Working with the FLF to fund innovative follicular lymphoma research through the Research United to CURE FL Awards and other shared initiatives.

Blood Cancer UK - Partnering with the FLF to deepen understanding of follicular lymphoma and support progress toward more tailored therapies.

DKMS - Supporting the FLF's cure-focused research into new treatment approaches and technologies that could help improve outcomes for people living with follicular lymphoma.

Patient Group Partnerships - Working closely with global online communities that provide safe spaces, shared experience and support for thousands of people affected by follicular lymphoma. This includes the Living with FL Facebook group and Linfoma folicular: Comunidad Internacional de Pacientes y Familiares grupo.

Working across the wider field

Alongside our research and funding partnerships, the FLF works with clinicians, industry partners, healthcare educators and scientific communities where there is clear alignment with our mission and direct value for patients. The FLF's independence remains central. We work with partners to strengthen patient voice, improve understanding and support better outcomes, while keeping patient need and cure-focused progress at the centre.

3. Plans for future periods

2025 showed what focused funding, patient insight and scientific collaboration can make possible, while reinforcing the challenge ahead: as research advances, progress must stay focused on the outcomes that matter most to people living with follicular lymphoma.
In the next phase, FLF is focused on turning this progress into stronger evidence, better-informed decisions, deeper patient involvement, more aligned funding, clearer pathways from discovery to patient benefit, and insights that can inform research beyond follicular lymphoma.

What we are focused on next	What progress looks like
Moving cure-focused science closer to patients. Building on our CURE FL portfolio to support research to understand what drives follicular lymphoma, identify people at greater risk, tackle relapse and treatment resistance, and improve treatment approaches.	Stronger evidence, clearer next steps and, where appropriate, the potential to inform future clinical studies.
Accelerating the development of new treatment approaches. Collaborating with partners to advance precision medicine-guided clinical trials and accelerate approval of innovative treatments for relapsed follicular lymphoma.	Approval and availability of treatments with breakthrough designation (when regulators recognise potential to significantly improve patient outcomes) for relapsed follicular lymphoma, bringing new options to patients sooner.
Making treatment more personalized. Advancing biomarker research, PETReA Plus and other data-driven work to better understand who may need treatment, when, which treatment may be most appropriate and how care can be better tailored to each person.	Better tools and evidence to support more informed treatment decisions, reduce unnecessary treatment and side effects, and improve outcomes for different groups of patients.
Ensuring patient insight shapes what comes next. Using surveys, discussion sessions, patient meet-ups and patient contributors to understand what matters most in real life, including treatment preferences, uncertainty, communication and clinical trial decisions.	Research priorities, educational resources, partnerships and measures of success that continue to be clearly grounded in the needs and experiences of people living with follicular lymphoma.
Building partnerships that accelerate progress. Working with researchers, clinicians, nonprofit organizations, funders, industry partners and patient communities to pool resources, share expertise and reduce duplication.	More aligned funding, shared learning and faster movement from scientific discovery toward patient benefit.

Together, these areas will guide FLF's continued work to turn promising science into better answers, better treatment decisions, longer-lasting responses and, ultimately, cure, while generating knowledge that can benefit research far beyond follicular lymphoma.

4. Financial Review

4.1. Financial Position

The financial statements for the year ended 31 December 2025 show a surplus of £47,078. This positive result reflects the continued support of our donors and partners, together with prudent financial management throughout the year.

The charity remains in a strong financial position, providing a solid foundation from which to expand its activities and further advance its charitable objectives in the years ahead.

4.2. Reserves Policy

As of 31 December 2025, the charity's total funds and reserves amounted to £1,286,694.

The charity operates with a lean cost structure and carefully manages its resources to maximise the funds available for charitable activities.

The Trustees have established a reserves policy designed to ensure the charity maintains sufficient financial stability to manage operational risks and meet its ongoing commitments.

The Trustees have determined that free reserves should be maintained at a level equivalent to approximately three months of planned expenditure. This level is considered appropriate in light of the charity's operating model, committed expenditure, fundraising profile and ability to manage costs and commitments through regular forecasting and Board oversight.

The Trustees will continue to monitor free reserves throughout the year against the approved budget and forecast cash requirements. In addition to maintaining the formal reserves policy, the Trustees will seek to strengthen the charity's broader financial resilience over time by diversifying income, managing expenditure carefully and building the funds available to support future growth and long-term sustainability.

4.3. Going Concern

The Trustees have assessed the charity's financial position, future plans and cash flow forecasts and are satisfied that it remains appropriate to prepare the financial statements on a going concern basis.

This assessment is supported by an approved business plan and budget covering the period to December 2027. The charity undertakes regular financial planning and monitoring, including the preparation of updated forecasts throughout the year, enabling expenditure and resource requirements to be reviewed in detail while maintaining a long-term strategic focus.

The Trustees continue to explore opportunities to strengthen the charity's long-term financial sustainability and diversify income streams. This supports the formal reserves policy by increasing financial flexibility and resilience, while ensuring that resources remain available to deliver the charity's approved plans and charitable objectives.

The charity has also continued to strengthen its organisational structure and operational capacity, demonstrating its commitment to delivering its charitable objectives over the long term.

Having considered the charity's financial resources, forecast income and expenditure, and future plans, the Trustees have a reasonable expectation that the charity has adequate resources to continue operating for the foreseeable future. Accordingly, they consider the going concern basis of accounting to be appropriate in preparing these financial statements.

4.4. Principal Risks and Uncertainties

The Trustees are responsible for identifying, assessing and managing the principal risks facing the charity and for ensuring that appropriate systems and controls are in place. During the year, the Trustees reviewed the charity's risk profile, with particular focus on the risks most relevant to FLF's scale, international activities, research funding model and reliance on donor support.

The principal risks considered by the Trustees include: income volatility and concentration risk, given the importance of major donors and philanthropic partnerships; research delivery risk, including the need to ensure grants are awarded, monitored and evaluated effectively; regulatory and compliance risk across the charity's UK and international operating context; data protection and information governance risk, particularly where patient engagement, surveys and digital communications are involved; people and capacity risk as the organisation grows; and reputational risk arising from the charity's public profile, partnerships and patient-facing activities.

These risks are managed through Board oversight, regular financial reporting and forecasting, grant governance and milestone review, due diligence on partners and funded activities, appropriate policies and procedures, data protection controls, insurance cover and ongoing review of organisational capacity. The Trustees also seek external professional advice where required, including in relation to legal, regulatory, employment and financial matters.

The Trustees are satisfied that appropriate policies, procedures and controls are in place to reduce the charity's principal risks to an acceptable level and to provide reasonable assurance against fraud, error and non-compliance. As FLF's activities, partnerships and international reach continue to develop, the Trustees will keep the risk management framework under review and strengthen it where needed.

4.5. Structure, governance and management

The Follicular Lymphoma Foundation ("FLF") is a charitable company, incorporated in England and Wales and registered with both the Charity Commission for England and Wales and Companies House.

The charitable company was incorporated on 12 April 2019 and is governed by its Memorandum and Articles of Association, which set out the charity's objects, powers and governance arrangements.

FLF was registered as a charity with the Charity Commission on 29 August 2019. The Trustees, who are also the directors of the charitable company for the purposes of company law, are responsible for the overall governance and strategic direction of the charity and for ensuring that it pursues its charitable objectives in accordance with its governing documents and applicable legislation.

The Follicular Lymphoma Foundation operates through three separate legal entities, each established and regulated within its respective jurisdiction:

- **The Follicular Lymphoma Foundation (FLF UK)** – a charitable company incorporated in England and Wales and registered with the Charity Commission for England and Wales and Companies House.
- **The Follicular Lymphoma Foundation US Inc. (FLF US)** – a registered 501(c)(3) charitable organisation in the United States with Employer Identification Number (EIN) 84-2338899.

- **The Follicular Lymphoma Foundation (FLF) Israel Ltd. (FLF Israel)** – an Israeli registered charity recognised under Section 46 of the Israeli Income Tax Ordinance, with company registration number 516798477.

Each organisation is a separate legal entity with its own governing board, statutory obligations and independent audit. While legally distinct, the three charities operate in close collaboration to deliver the Foundation's global mission. Many research, fundraising and operational programmes are undertaken jointly across the entities to maximise impact and ensure coordinated delivery.

FLF UK provides central operational and administrative support to FLF US and FLF Israel, including finance, governance and other shared services. The costs of these services are recharged to the respective entities in accordance with agreed arrangements and are subject to approval by each entity's Board of Directors or Trustees, as appropriate.

4.5.1. Decision Making

The Board of Trustees meets formally at least four times each year and is responsible for setting the strategic direction of the charity, establishing key policies, and overseeing the effective delivery of its charitable objectives.

The Trustees monitor the charity's performance, financial position, risk management framework and the impact of its activities, ensuring that resources are used effectively and in furtherance of the charity's mission.

The Board comprises individuals with a diverse range of professional skills, expertise and experience relevant to the charity's activities, including governance, finance, fundraising, research, healthcare, business and communications. This breadth of knowledge supports robust decision-making and effective oversight of the charity's operations and long-term development.

4.5.2. Statement of Trustees' Responsibilities

The Trustees (who are also the directors of the Follicular Lymphoma Foundation for the purposes of company law) are responsible for preparing the Report of the Trustees and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice) including Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland".

Company law requires the Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period.

In preparing those financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently
- observe the methods and principles in the Charity SORP
- make judgements and estimates that are reasonable and prudent
- state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements
- prepare the financial statements on a going concern basis unless it is inappropriate to presume that the charitable company will continue in business

The Trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the charitable company and to enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

So far as the Trustees are aware: there is no relevant audit information of which the charitable company's auditors are unaware; and

- the Trustees have taken all steps that they ought to have taken to make themselves aware of any relevant audit information and to establish that the auditors are aware of that information.

5. Auditors

The auditors, Cooper Parry Group Limited, will be proposed for re-appointment at the forthcoming Annual General Meeting.

Report of the Trustees, incorporating a strategic report, approved by order of the board of

Trustees, as the company directors, on 25 September 2026 and signed on the board's behalf

by:

Signed by:

.....AB8DA62894BA47B.....

Lord J N Mendelsohn - Trustee

Docusign Envelope ID: 305A85A8-8AD4-8AE4-8122-F6BDC1A8E87A

FOLLICULAR LYMPHOMA FOUNDATION

(A company limited by guarantee)

INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF FOLLICULAR LYMPHOMA FOUNDATION

Opinion

We have audited the financial statements of Follicular Lymphoma Foundation (the 'charitable company') for the year ended 31 December 2025 which comprise the Statement of financial activities, the Balance sheet, the Statement of cash flows and the related notes, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the charitable company's affairs as at 31 December 2025 and of its incoming resources and application of resources, including its income and expenditure for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Charities Act 2011.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the United Kingdom, including the Financial Reporting Council's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the Trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the Trustees with respect to going concern are described in the relevant sections of this report.

signature:2c9944044a71f5cc5d6f47c5b64e1da16c36398dbf7ba536cd2070f7cff17034

FOLLICULAR LYMPHOMA FOUNDATION

(A company limited by guarantee)

INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF FOLLICULAR LYMPHOMA FOUNDATION (CONTINUED)

Other information

The other information comprises the information included in the Annual report other than the financial statements and our Auditor's report thereon. The Trustees are responsible for the other information contained within the Annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Matters on which we are required to report by exception

We have nothing to report in respect of the following matters where the Charities (Accounts and Reports) Regulations 2008 requires us to report to you if, in our opinion:

- the information given in the Trustees' report is inconsistent in any material respect with the financial statements; or
- sufficient accounting records have not been kept; or
- the financial statements are not in agreement with the accounting records and returns; or
- we have not received all the information and explanations we require for our audit.

Responsibilities of trustees

As explained more fully in the Trustees' responsibilities statement, the Trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the Trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Trustees are responsible for assessing the charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

FOLLICULAR LYMPHOMA FOUNDATION

(A company limited by guarantee)

INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF FOLLICULAR LYMPHOMA FOUNDATION (CONTINUED)

Auditor's responsibilities for the audit of the financial statements

We have been appointed as auditor under section 145 of the Charities Act 2011 and report in accordance with the Act and relevant regulations made or having effect thereunder.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an Auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

Our assessment focussed on key laws and regulations the charitable company has to comply with and areas of the financial statements we assessed as being more susceptible to misstatement. These key laws and regulations included but were not limited to compliance with the Companies Act 2006, Charities Act 2011, Trustees Act 2000, Charities (Protection and Social Investment) Act 2016, taxation legislation, data protection and employment legislation.

We are not responsible for preventing irregularities, including fraud. Our approach to detecting irregularities, including fraud, included, but was not limited to, the following:

- obtaining an understanding of the legal and regulatory framework applicable to the charitable company and how the charitable company is complying with that framework, including agreement of financial statement disclosures to underlying documentation and other evidence;
- obtaining an understanding of the charitable company's control environment and how the charitable company has applied relevant control procedures, through discussions with Trustees and other management and by performing walkthrough testing over key areas;
- obtaining an understanding of the charitable company's risk assessment process, including the risk of fraud;
- reviewing meeting minutes of those charged with governance throughout the year; and
- performing audit testing to address the risk of management override of controls, including testing journal entries and other adjustments for appropriateness, evaluating the business rationale of significant transactions outside the normal course of business and reviewing accounting estimates for bias.

Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our Auditor's report.

FOLLICULAR LYMPHOMA FOUNDATION
(A company limited by guarantee)

INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF FOLLICULAR LYMPHOMA FOUNDATION (CONTINUED)

Use of our report

This report is made solely to the charitable Company's members, as a body, in accordance with Part 4 of the Charities (Accounts and Reports) Regulations 2008. Our audit work has been undertaken so that we might state to the charitable Company's members those matters we are required to state to them in an Auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable Company and its members, as a body, for our audit work, for this report, or for the opinions we have formed.

Signed by:
A9A4E4D5295D40E...

Nichola Hodgetts (Senior Statutory Auditor)
for and on behalf of
Cooper Parry Group Limited
Cubo Birmingham
4th Floor
Two Chamberlain Square
Birmingham
B3 3AX

25 September 2026

Cooper Parry Group Limited are eligible to act as auditors in terms of section 1212 of the Companies Act 2006.

Docusign Envelope ID: 305A85A8-8AD4-8AE4-8122-F6BDC1A8E87A

FOLLICULAR LYMPHOMA FOUNDATION
(A company limited by guarantee)

STATEMENT OF FINANCIAL ACTIVITIES (INCORPORATING INCOME AND EXPENDITURE ACCOUNT) FOR THE YEAR ENDED 31 DECEMBER 2025

	Note	Restricted funds 2025 £	Unrestricted funds 2025 £	Total funds 2025 £	Total funds 2024 £
Income from:					
Donations and legacies	3	958,784	1,451,472	2,410,256	2,384,538
Investments	4	-	5,776	5,776	7,241
Other income	5	-	89,212	89,212	-
Total income		958,784	1,546,460	2,505,244	2,391,779
Expenditure on:					
Raising funds	6	-	250,928	250,928	224,630
Charitable activities:	7,8				
Research and patient programmes		870,849	1,114,792	1,985,641	2,041,408
Research and patient programme support costs		-	221,597	221,597	150,479
Total expenditure		870,849	1,587,317	2,458,166	2,416,517
Net income/(expenditure)		87,935	(40,857)	47,078	(24,738)
Transfers between funds	15	40,276	(40,276)	-	-
Net movement in funds		128,211	(81,133)	47,078	(24,738)
Reconciliation of funds:					
Total funds brought forward		137,074	1,102,542	1,239,616	1,264,354
Net movement in funds		128,211	(81,133)	47,078	(24,738)
Total funds carried forward		265,285	1,021,409	1,286,694	1,239,616

Continuing operations
All income and expenditure has arisen from continuing activities.

signature:2c9944044a71f5cc6d6f47c5b64e1da16c36388dbf7ba586cd2070f7cff17034

Docusign Envelope ID: 305A85A8-8AD4-8AE4-8122-F6BDC1A8E87A

FOLLICULAR LYMPHOMA FOUNDATION
(A company limited by guarantee)
REGISTERED NUMBER: 11943477

BALANCE SHEET
AS AT 31 DECEMBER 2025

	Note		2025 £		2024 £
Fixed assets					
Tangible assets	12		9,074		7,381
			9,074		7,381
Current assets					
Debtors	13	1,043,887		212,674	
Cash at bank and in hand	18	988,906		1,805,674	
		2,032,793		2,018,348	
Current liabilities					
Creditors: amounts falling due within one year	14	(755,173)		(786,113)	
Net current assets			1,277,620		1,232,235
Total net assets			1,286,694		1,239,616
Charity funds					
Restricted funds	15		265,285		137,074
Unrestricted funds	15		1,021,409		1,102,542
Total funds			1,286,694		1,239,616

These financial statements have been prepared in accordance with the provisions applicable to charitable companies subject to the small companies regime.

The financial statements were approved and authorised for issue by the Trustees and signed on their behalf by:

Signed by:

.....AB8DA62894BA47B.....
Lord J N Mendelsohn - Trustee

Date: 25 September 2026

signature:2c9944044a71f5cc6d6fa7c3b64e1da13c35338dbf7ba586cd2070f7cff17034

Docusign Envelope ID: 305A85A8-8AD4-8AE4-8122-F6BDC1A8E87A

FOLLICULAR LYMPHOMA FOUNDATION
(A company limited by guarantee)

STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED 31 DECEMBER 2025

	2025 £	2024 £
Cash flows from operating activities		
Cash generated from operations	(817,511)	515,458
Cash flows from investing activities:		
Purchase of tangible fixed assets	(5,033)	(4,397)
Interest received	5,776	7,241
Net cash (used in)/provided by investing activities	743	2,844
Change in cash and cash equivalents in the year	(816,768)	518,302
Cash and cash equivalents at the beginning of the year	1,805,674	1,287,372
Cash and cash equivalents at the end of the year	988,906	1,805,674

signature:2c9944044a71f5cc6d6f47c5b64e1da16c36388dbf7ba586cd2070f7cff17034

Docusign Envelope ID: 305A85A8-8AD4-8AE4-8122-F6BDC1A8E87A

FOLLICULAR LYMPHOMA FOUNDATION
(A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

1. Accounting policies

1.1 Basis of preparation of financial statements

Follicular Lymphoma Foundation is a private company limited by guarantee, and is a registered charity incorporated in England and Wales under the Companies Act 2006. The charity is registered with the Charity Commission for England and Wales (Charity No: 1185091).

The financial statements have been prepared in accordance with the Charities SORP (FRS 102) - Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

The financial statements are presented in GBP (£), which is the presentational currency of the charity.

The charity meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy. Individual figures are reported in whole numbers, rounded to the nearest £1.

1.2 Going concern

The financial statements have been prepared on a going concern basis. The Trustees have reviewed and considered relevant information, including the annual budget and future cash flows in making their assessment. Based on these assessments, and the current resources available, the Trustees have concluded that they can continue to adopt the going concern basis in preparing the annual report and accounts.

1.3 Income

All income is recognised once the Company has entitlement to the income, it is probable that the income will be received and the amount of income receivable can be measured reliably.

Donations are recognised when the charity is entitled to the income, receipt is probable and the amount can be measured reliably. Restricted donations are credited to the appropriate restricted fund. Donations subject to conditions that have not been met at the year-end are deferred until those conditions are satisfied. Gift Aid is recognised when the related donation is recognised.

Interest receivable is recognised in the Statement of Financial Activities on an accruals basis as it is earned.

1.4 Donated goods, services and volunteers

Donated goods, services and facilities are recognised as income at fair value when receipt is probable and the value can be measured reliably, with an equivalent amount recognised as expenditure or as an asset as appropriate. The time given by volunteers is not recognised in the financial statements; the role of volunteers is described in the Trustees' report.

FOLLICULAR LYMPHOMA FOUNDATION
(A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

1. Accounting policies (continued)

1.5 Expenditure

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges allocated on the portion of the asset's use.

Expenditure on raising funds includes all expenditure incurred by the Company to raise funds for its charitable purposes and includes costs of all fundraising activities events and non-charitable trading.

Expenditure on charitable activities is incurred on directly undertaking the activities which further the Company's objectives, as well as any associated support costs.

Costs of activities include support costs and governance costs which have been allocated between activities on the basis set out below.

Support Costs
Support costs are those functions that assist the work of the charity but do not directly undertake charitable activities. Support costs include central office functions such as finance, human resources, information technology and general management. These costs have been allocated between activities on the basis of staff time spent on each activity, which the Trustees consider to be the most appropriate basis given the nature of the costs incurred.

Governance costs
Governance costs include costs of the preparation and examination of the statutory accounts, the costs of trustee meetings and the cost of any legal advice on governance matters.

1.6 Grants and research funding

Grants and research funding payable in furtherance of the charity's objects are recognised as expenditure, and a corresponding liability, once there is a legal or constructive obligation committing the charity to the payment and the amount can be measured reliably. Where funding is conditional on future performance or events within the charity's control, it is recognised only as those conditions are met.

1.7 Taxation

The Company is considered to pass the tests set out in Paragraph 1 Schedule 6 of the Finance Act 2010 and therefore it meets the definition of a charitable company for UK corporation tax purposes. Accordingly, the Company is potentially exempt from taxation in respect of income or capital gains received within categories covered by Chapter 3 Part 11 of the Corporation Tax Act 2010 or Section 256 of the Taxation of Chargeable Gains Act 1992, to the extent that such income or gains are applied exclusively to charitable purposes.

The charity is not registered for VAT. Irrecoverable VAT is included within the cost of the expenditure or asset to which it relates.

signature:2c9944044a71f5cc8d6f47c5b64e1da16c36238d0f7ba586cd2070f7cff170d4

FOLLICULAR LYMPHOMA FOUNDATION
(A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

1. Accounting policies (continued)

1.8 Tangible fixed assets and depreciation

Tangible fixed assets are initially recognised at cost. After recognition, under the cost model, tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. All costs incurred to bring a tangible fixed asset into its intended working condition should be included in the measurement of cost.

Depreciation is charged so as to allocate the cost of tangible fixed assets less their residual value over their estimated useful lives, using the straight-line method.

Depreciation is provided on the following basis:

Computer equipment	-	33%

1.9 Currency

The functional and presentation currency of the charity is pounds sterling (£), being the currency of the primary economic environment in which it operates. Transactions in foreign currencies are translated at the rate ruling at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies at the balance sheet date are retranslated at the closing rate. All exchange gains and losses are recognised in the Statement of Financial Activities in the period in which they arise. The charity does not use hedging instruments.

1.10 Debtors

Trade and other debtors are recognised at the settlement amount after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

1.11 Cash at bank and in hand

Cash at bank and in hand includes cash and short-term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

1.12 Liabilities and provisions

Liabilities are recognised when there is an obligation at the Balance sheet date as a result of a past event, it is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be estimated reliably.

Liabilities are recognised at the amount that the Company anticipates it will pay to settle the debt or the amount it has received as advanced payments for the goods or services it must provide.

Provisions are measured at the best estimate of the amounts required to settle the obligation. Where the effect of the time value of money is material, the provision is based on the present value of those amounts, discounted at the pre-tax discount rate that reflects the risks specific to the liability. The unwinding of the discount is recognised in the Statement of financial activities as a finance cost.

1.13 Pensions

The charitable company operates a defined contribution pension scheme. Contributions payable to the charitable company's pension scheme are charged to the Statement of Financial Activities in the period to which they relate.

Docusign Envelope ID: 305A85A8-8AD4-8AE4-8122-F6BDC1A8E87A

1. Accounting policies (continued)

1.14 Fund accounting

General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the Company and which have not been designated for other purposes.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the Company for particular purposes. The costs of raising and administering such funds are charged against the specific fund. The aim and use of each restricted fund is set out in the notes to the financial statements.

Investment income, gains and losses are allocated to the appropriate fund.

2. *Critical accounting estimates and areas of judgment*

In preparing the financial statements, Management are required to make judgements, estimates and assumptions that affect the reported amounts of assets, liabilities, income and expenditure. Estimates and underlying assumptions are based on historical experience and other factors considered reasonable in the circumstances, and are reviewed on an ongoing basis. Actual results may differ from these estimates.
The areas involving a higher degree of judgement, or where assumptions and estimates are significant to the financial statements, are:

Research grant and programme commitments - judgement is applied in determining whether a legal or constructive obligation exists at the year end, and the amount at which any resulting liability is recognised. The most significant such commitment is included within accruals (note 14).

Accrued income - judgement and estimation are applied in determining entitlement to income receivable but not yet received at the year end, and the amount at which it is recognised (note 13).

Critical accounting estimates and assumptions:

The Company makes estimates and assumptions concerning the future. The resulting accounting estimates and assumptions will, by definition, seldom equal the related actual results.

Signature: 2c9944044a71f5cc6d6f47c5b64e1da16c36388dbf7ba586cd2070f7cff17034

FOLLICULAR LYMPHOMA FOUNDATION
(A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

3. Income from donations

	Restricted funds 2025 £	Unrestricted funds 2025 £	Total funds 2025 £
Donations	958,784	1,340,774	2,299,558
Donated Services	-	110,698	110,698
Total 2025	958,784	1,451,472	2,410,256

Donated services principally comprise legal and communications support. These are recognised as income at the fair value of the services received at the date of donation, based on the estimated value to the charity, with an equivalent amount recognised as expenditure in the year.

	Restricted funds 2024 £	Unrestricted funds 2024 £	Total funds 2024 £
Donations	960,914	1,423,624	2,384,538

4. Investment income

	Unrestricted funds 2025 £	Total funds 2025 £
Deposit account interest	5,776	5,776

	Unrestricted funds 2024 £	Total funds 2024 £
Deposit account interest	7,241	7,241

FOLLICULAR LYMPHOMA FOUNDATION
(A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

5. Other income

	Unrestricted funds 2025 £	Total funds 2025 £	Total funds 2024 £
Recharge of shared costs with FLF US	89,212	89,212	-

6. Expenditure on raising funds

Fundraising trading expenses

	Unrestricted funds 2025 £	Total funds 2025 £
Fundraising fees	13,805	13,805
Allocation of overheads	25,999	25,999
Event costs	117,127	117,127
Fundraising trading expenses - wages and salaries	81,819	81,819
Fundraising trading expenses - NI	10,905	10,905
Fundraising trading expenses - pension costs	1,273	1,273
Total 2025	250,928	250,928

	Unrestricted funds 2024 £	Total funds 2024 £
Fundraising fees	1,431	1,431
Allocation of overheads	28,912	28,912
Event costs	107,893	107,893
Fundraising trading expenses - wages and salaries	76,104	76,104
Fundraising trading expenses - NI	9,678	9,678
Fundraising trading expenses - pension costs	612	612
Total 2024	224,630	224,630

FOLLICULAR LYMPHOMA FOUNDATION
(A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

7. Analysis of expenditure on charitable activities

Summary by fund type

	Restricted funds 2025 £	Unrestricted funds 2025 £	Total 2025 £
Research and patient programmes (including governance costs)	781,637	1,114,792	1,896,429
Intercompany staff costs recharged	89,212	-	89,212
Research and patient programme support costs	-	221,597	221,597
Total 2025	870,849	1,336,389	2,207,238

	Restricted funds 2024 £	Unrestricted funds 2024 £	Total 2024 £
Research and patient programmes (including governance costs)	1,369,078	670,662	2,039,740
Research and patient programme support costs	-	152,147	152,147
Total 2024	1,369,078	822,809	2,191,887

8. Analysis of expenditure by activities

	Direct research and patient programmes 2025 £	Governance research and patient programme support costs 2025 £	Total funds 2025 £
Research and patient programmes	1,873,764	22,665	1,896,429
Intercompany staff costs recharged	89,212	-	89,212
Research and patient programme support costs	-	221,597	221,597
Total 2025	1,962,976	244,262	2,207,238

FOLLICULAR LYMPHOMA FOUNDATION
(A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

8. Analysis of expenditure by activities (continued)

	Direct research and patient programmes 2024 £	Governance research and patient programme support costs 2024 £	Total funds 2024 £
Research and patient programmes	2,020,780	18,960	2,039,740
Research and patient programme support costs	-	152,147	152,147
Total 2024	2,020,780	171,107	2,191,887

Analysis of support costs

	Governance Costs 2025 £	Research and patient programme support costs 2025 £	Total funds 2025 £
Staff costs	-	132,403	132,403
Marketing and Communications	-	50,027	50,027
IT support costs	-	25,900	25,900
Travel and accommodation	-	1,521	1,521
Bank charges	-	2,539	2,539
Database & CRM	-	21,761	21,761
Postage and stationery	-	1,144	1,144
Legal expenses	-	77,023	77,023
Depreciation	-	3,340	3,340
General and other	-	1,795	1,795
Operating lease expenses	-	29,004	29,004
Event costs	-	1,203	1,203
Staff training	-	167	167
Staff training and Recruitment	-	23,838	23,838
Re-allocation of overheads to direct programmes	-	(176,809)	(176,809)
Foreign exchange losses	-	26,741	26,741
Governance costs	22,665	-	22,665
Total 2025	22,665	221,597	244,262

FOLLICULAR LYMPHOMA FOUNDATION
(A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

8. Analysis of expenditure by activities (continued)

Analysis of support costs (continued)

	Governance Costs 2024 £	Research and patient programme support costs 2024 £	Total funds 2024 £
Staff costs	-	182,444	182,444
Marketing and Communications	-	42,190	42,190
Support and consultancy	-	28,760	28,760
IT and support	-	16,229	16,229
Travel and accommodation	-	470	470
Bank charges	-	2,422	2,422
Database & CRM	-	18,064	18,064
Postage and stationery	-	395	395
Administrative support	-	13,857	13,857
Legal expenses	-	3,845	3,845
Depreciation	-	2,015	2,015
General and other	-	2,797	2,797
Operating lease costs	-	24,344	24,344
Staff training and Recruitment	-	46,777	46,777
Re-allocation of overheads to direct programmes	-	(226,265)	(226,265)
Foreign exchange gain	-	(6,197)	(6,197)
Governance costs	18,960	-	18,960
Total 2024	18,960	152,147	171,107

Where grant agreements provide for the recovery of a contribution towards the charity's central costs, that funded element is recognised within the direct costs of the relevant charitable activity ('cost recovery'). Central costs that are not recovered from funders are apportioned across the charity's activities and shown as support costs. This ensures that costs met by funders are reported against the activity they support, while the residual cost of running the charity is transparently disclosed as support cost.

9. Auditor's remuneration

	2025 £	2024 £
Fees payable to the Company's auditor for the audit of the Company's annual accounts	15,000	13,500

FOLLICULAR LYMPHOMA FOUNDATION
(A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

10. Staff costs

	2025 £	2024 £
Wages and salaries	680,871	612,299
Social security costs	92,684	74,976
Contribution to defined contribution pension schemes	7,504	6,680
	781,059	693,955

The average number of persons employed by the Company during the year was as follows:

	2025 No.	2024 No.
Employees	9	7

The average headcount distinguished between full time and part time staff are as follows:

	2025 No.	2024 No.
Full time employees	5	6
Part time employees	4	1
	9	7

The number of employees whose employee benefits (excluding employer pension costs) exceeded £60,000 was:

	2025 No.	2024 No.
In the band £60,001 - £70,000	-	2
In the band £70,001 - £80,000	1	-
In the band £90,001 - £100,000	1	2
In the band £220,001 - £230,000	-	1
In the band £240,001 - £250,000	1	-

Key management personnel comprise the members of the Senior Management Team, being those persons having authority and responsibility for planning, directing and controlling the activities of the charity. The total employee benefits of key management personnel were £478,179 (2024: £412,310).

FOLLICULAR LYMPHOMA FOUNDATION
(A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

11. Trustees' remuneration and expenses

During the year, no Trustees received any remuneration or other benefits (2024 - £Nil).

Donations from Trustees
During the period, the total aggregate amount of unrestricted donations from Trustees was £82,750 (2024: £84,000).

During the year ended 31 December 2025, no Trustee expenses have been incurred (2024 - £Nil).

12. Tangible fixed assets

	Computer equipment £
Cost or valuation	
At 1 January 2025	19,661
Additions	5,033
At 31 December 2025	24,694
Depreciation	
At 1 January 2025	12,280
Charge for the year	3,340
At 31 December 2025	15,620
Net book value	
At 31 December 2025	9,074
At 31 December 2024	7,381

FOLLICULAR LYMPHOMA FOUNDATION
(A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

13. Debtors

	2025 £	2024 £
Due within one year		
Trade debtors	409,330	200,631
Prepayments and accrued income	634,557	12,043
	1,043,887	212,674

14. Creditors: Amounts falling due within one year

	2025 £	2024 £
Trade creditors	126,348	18,262
Other taxation and social security	25,362	22,558
Other Creditors	2,220	1,937
Accruals and deferred income	601,243	743,356
	755,173	786,113

The amount of deferred income included in accruals and deferred income is £nil (2024: £nil).

FOLLICULAR LYMPHOMA FOUNDATION
(A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

15. Statement of funds

Statement of funds - current year

	Balance at 1 January 2025 £	Income £	Expenditure £	Transfers between funds £	Balance at 31 December 2025 £
Unrestricted funds					
Unrestricted funds	1,102,542	1,546,460	(1,587,317)	(40,276)	1,021,409

	Balance at 1 January 2025 £	Income £	Expenditure £	Transfers between funds £	Balance at 31 December 2025 £
Restricted funds					
Mark Foundation for Cancer Research - towards CURE FL research	70,832	-	-	-	70,832
DKMS Stiftung Leben Spenden	(50,532)	632,111	(621,855)	40,276	-
CURE FL	78,966	226,673	(165,894)	-	139,745
Blood Cancer UK	12,654	-	(12,654)	-	-
The Joyce & Norman Freed Charitable Trust	25,154	100,000	(70,446)	-	54,708
	137,074	958,784	(870,849)	40,276	265,285
Total of funds	1,239,616	2,505,244	(2,458,166)	-	1,286,694

The Mark Foundation
The funds are to fund one Momentum Fellow, a postdoctoral researcher conducting evidence-based laboratory, data, and/or medical science research at a non-profit institution.

DKMS Stiftung Leben Spenden
The funds are to fund feasibility and Phase 2a clinical trial evaluating the safety, feasibility, and preliminary effectiveness of huCART19-IL18 therapy administered without lymphodepletion in patients with relapsed or refractory follicular lymphoma.

CURE FL
This programme brings together the Blood Cancer United (BCU) formerly Leukemia & Lymphoma Society (LLS), the Follicular Lymphoma Foundation (FLF), and the Institute for Follicular Lymphoma Innovation (IFLI) to jointly fund high-quality, innovative research that advances the treatment of follicular lymphoma.

Blood Cancer UK & The Joyce & Norman Freed Charitable Trust
Funding to identify treatment patterns, clinical outcomes and risk clusters for newly diagnosed FL (FL) and de novo transformed FL (tFL) undergoing treatment.

FOLLICULAR LYMPHOMA FOUNDATION
(A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

15. Statement of funds (continued)

Statement of funds - prior year

	Balance at 1 January 2024 £	Income £	Expenditure £	Transfers between funds £	Balance at 31 December 2024 £
Unrestricted funds					
Unrestricted funds	1,103,336	1,430,865	(1,047,439)	(384,220)	1,102,542

	Balance at 1 January 2024 £	Income £	Expenditure £	Transfers between funds £	Balance at 31 December 2024 £
Restricted funds					
Maurice Wohl Charitable Foundation - towards Cure FL research	90,186	-	(173,936)	83,750	-
Mark Foundation for Cancer Research - towards CURE FL research	70,832	-	-	-	70,832
DKMS Stiftung Leben Spenden	-	526,840	(577,372)	-	(50,532)
CURE FL	-	246,574	(468,078)	300,470	78,966
Blood Cancer UK	-	87,500	(74,846)	-	12,654
The Joyce & Norman Freed Charitable Trust	-	100,000	(74,846)	-	25,154
	161,018	960,914	(1,369,078)	384,220	137,074
Total of funds	1,264,354	2,391,779	(2,416,517)	-	1,239,616

FOLLICULAR LYMPHOMA FOUNDATION
(A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

16. Analysis of net assets between funds

Analysis of net assets between funds - current year

	Restricted funds 2025 £	Unrestricted funds 2025 £	Total funds 2025 £
Tangible fixed assets	-	9,074	9,074
Current assets	265,285	1,767,508	2,032,793
Creditors due within one year	-	(755,173)	(755,173)
Total	265,285	1,021,409	1,286,694

Analysis of net assets between funds - prior year

	Restricted funds 2024 £	Unrestricted funds 2024 £	Total funds 2024 £
Tangible fixed assets	-	7,381	7,381
Current assets	137,074	1,881,274	2,018,348
Creditors due within one year	-	(786,113)	(786,113)
Total	137,074	1,102,542	1,239,616

17. Reconciliation of net movement in funds to net cash flow from operating activities

	2025 £	2024 £
Net income/expenditure for the year (as per Statement of Financial Activities)	47,078	(24,738)
Adjustments for:		
Depreciation charges	3,340	2,015
Interest received	(5,776)	(7,241)
(Increase)/decrease in debtors	(831,213)	(128,828)
Increase/(decrease) in creditors	(30,940)	674,250
Net cash provided by/(used in) operating activities	(817,511)	515,458

FOLLICULAR LYMPHOMA FOUNDATION
(A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

18. Analysis of cash and cash equivalents

	2025 £	2024 £
Cash in hand	988,906	1,805,674
Total cash and cash equivalents	988,906	1,805,674

19. Analysis of changes in net debt

	At 1 January 2025 £	Cash flows £	At 31 December 2025 £
Cash at bank and in hand	1,805,674	(816,768)	988,906
Debt due within 1 year	(1,937)	(283)	(2,220)
	1,803,737	(817,051)	986,686

20. Members' liability

The charitable company is limited by guarantee and has no share capital. In the event of the charitable company being wound-up, the liability in respect of the guarantee is limited to £10 per member of the charitable company during the time they are a member or within one year of ceasing to be a member, as stated in the Memorandum and Articles of Association.

21. Related party transactions

The charity is one of three affiliated organisations - the Follicular Lymphoma Foundation (UK), Follicular Lymphoma Foundation US, and Follicular Lymphoma Foundation Israel Ltd (a public benefit company) - which share common founding trustees/members and, in part, common management. The charity holds an equal membership interest, alongside six other members, in Follicular Lymphoma Foundation Israel Ltd; this interest carries no right to any distribution of profits or assets and is not considered to give the charity control. The charity has representation on the board of the Israeli entity.

During the year, the charity recharged £89,212 of shared costs to Follicular Lymphoma Foundation US, recognised as other income in note 5. Separately, the charity recognised £89,212 of staff costs incurred by Follicular Lymphoma Foundation US in respect of research programme activity, included as charitable expenditure in note 7. At the year end, £103,210 (2024: £nil) was receivable from Follicular Lymphoma Foundation US in respect of costs paid on its behalf.

The charity received donations totalling £27,750 (2024: £nil) from entities controlled by trustees, and £82,750 (2024: £84,000) of unrestricted donations from trustees (see note 11).

Trustee Lord Richard Irwin Harrington is a director of Harvington Properties Ltd. During the year, the charity purchased services from them totalling £31,671 (2024: £Nil). At the year end, the balance outstanding was £2,667.